BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1389934)

  • 21. Determination of oxycodone and its major metabolites in haematic and urinary matrices: Comparison of traditional and miniaturised sampling approaches.
    Protti M; Catapano MC; Samolsky Dekel BG; Rudge J; Gerra G; Somaini L; Mandrioli R; Mercolini L
    J Pharm Biomed Anal; 2018 Apr; 152():204-214. PubMed ID: 29414014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.
    Kokki M; Heikkinen M; Välitalo P; Hautajärvi H; Hokkanen J; Pitkänen H; Sankilampi U; Ranta VP; Kokki H
    Br J Clin Pharmacol; 2017 Apr; 83(4):791-800. PubMed ID: 27780305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.
    Andreassen TN; Klepstad P; Davies A; Bjordal K; Lundström S; Kaasa S; Dale O
    Eur J Clin Pharmacol; 2011 May; 67(5):493-506. PubMed ID: 21140139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone.
    Naito T; Takashina Y; Yamamoto K; Tashiro M; Ohnishi K; Kagawa Y; Kawakami J
    J Clin Pharmacol; 2011 Nov; 51(11):1529-38. PubMed ID: 21209234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
    Edwards SR; Smith MT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):264-70. PubMed ID: 17098487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
    Saari TI; Grönlund J; Hagelberg NM; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2010 Apr; 66(4):387-97. PubMed ID: 20076952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.
    Huang L; Edwards SR; Smith MT
    Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.
    Kokki H; Rasanen I; Reinikainen M; Suhonen P; Vanamo K; Ojanperä I
    Clin Pharmacokinet; 2004; 43(9):613-22. PubMed ID: 15217304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography.
    Cheremina O; Bachmakov I; Neubert A; Brune K; Fromm MF; Hinz B
    Biomed Chromatogr; 2005 Dec; 19(10):777-82. PubMed ID: 15920700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dialyzability of Oxycodone and Its Metabolites in Chronic Noncancer Pain Patients with End-Stage Renal Disease.
    Samolsky Dekel BG; Donati G; Vasarri A; Croci Chiocchini AL; Gori A; Cavallari G; Di Nino G; Mercolini L; Protti M; Mandrioli R; Melotti RM; La Manna G
    Pain Pract; 2017 Jun; 17(5):604-615. PubMed ID: 27589376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
    Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
    Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
    Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone.
    Beaver WT; Wallenstein SL; Rogers A; Houde RW
    J Pharmacol Exp Ther; 1978 Oct; 207(1):92-100. PubMed ID: 359779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
    Hale ME; Dvergsten C; Gimbel J
    J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of oral oxycodone in patients after total gastric resection.
    Szałek E; Karbownik A; Murawa D; Połom K; Tezyk A; Gracz J; Grabowski T; Grześkowiak E; Biczysko-Murawa A; Murawa P
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3126-33. PubMed ID: 25392115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.